Physician profile
James D Rossini
NPI 1225042039
$685.00
in general payments reported to CMS, 2019-2025
17 companies · $16.67 in 2025
The $16.67 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $164 · 2021: $145 · 2022: $129 · 2023: $57.28 · 2024: $48.71 · 2025: $16.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $122.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $117.37 | 2020-2024 | Otezla, Repatha |
| Novo Nordisk INC | $115.21 | 2019-2025 | Wegovy |
| Kowa Pharmaceuticals America, INC. | $88.07 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $71.25 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $41.83 | 2019-2022 | |
| Pfizer INC. | $36.04 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $28.73 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $27.76 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $25.68 | 2019-2022 | |
| Philips North America LLC | $24.73 | 2020-2021 | |
| Itamar Medical INC | $21.28 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.23 | 2020 | |
| Phathom Pharmaceuticals, INC. | $15.41 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.14 | 2022 | |
| Radius Health, INC. | $13.70 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12.63 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rossini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.